Verastem said preclinical data show avutometinib plus a FAK inhibitor may boost KRAS G12C inhibitor efficacy in non-small cell lung cancer models. The findings were published in Science; late-breaking RAMP data are due at IGCSociety2026.
published
Verastem said preclinical data show avutometinib plus a FAK inhibitor may boost KRAS G12C inhibitor efficacy in non-small cell lung cancer models. The findings were published in Science; late-breaking RAMP data are due at IGCSociety2026.
Latest documented BWB result
$NCPL · $GCDT · $SUNE market result
Here is my September recap 💥 Entry top percentage of move For sure i didn’t hold the full move on all of them, and for sure i got hit with a lot of losses, but i always manage to have a plan, stick to it, minimize losse…
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.